BackgroundHuman epidermal growth factor receptor 2 (HER-2) amplification has been identified in approximately 3% of patients with metastatic colorectal cancer (mCRC). Owing to the lack of established anti-ERBB2 therapeutic approaches. mCRC patients with Her-2 amplification rarely receive targeted treatments. Moreover. https://parisnaturalfoodes.shop/product-category/mens-50-multi/